Go to the list of all blogs
Allana's Avatar
published in Blogs
Nov 22, 2026
TickeronGET DAILY SIGNALS
Sanofi (SNY): Analyst Targets Point to +18% Upside Potential

Sanofi (SNY): Analyst Targets Point to +18% Upside Potential

Key Takeaways

  • The central $55 stock price target is the arithmetic mean of roughly a dozen current analyst price targets on SNY, and it implies roughly 18% upside from the latest close near $46.52.
  • Independent data aggregators report a similar average analyst price target of about $54.92, with individual targets ranging from roughly $45 to $63.
  • Sanofi's strongest support comes from double-digit constant-currency sales growth, led by the blockbuster Dupixent, and upgraded 2026 guidance after a strong third quarter.
  • Sentiment is split: several brokers downgraded the shares in 2025 and early 2026, while others raised targets again after the Q3 report.
  • Key risks include patent-loss (LOE) exposure beyond Dupixent, currency swings, and valuation re-rating pressure.
  • For more on this name, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
  • You can also explore Trending AI Robots for AI-driven market insights.

What the Analyst Consensus Shows

Sanofi, the French pharmaceutical group whose American Depositary Receipts trade as SNY on the Nasdaq, draws coverage from a broad but divided analyst base. Independent aggregators such as S&P Global and Yahoo Finance report a 12-month average price target near $54.92 across roughly 11 analysts, which rounds to the $55 central target used here. The individual targets span a wide band from about $45 to $63.

That spread reflects genuine disagreement among observers. Cautious, Hold-rated houses sit at the lower end — Morgan Stanley held a $49 target, and Exane BNP Paribas a $50 target, after both moved to neutral ratings. In the middle, TD Cowen maintained a $57 Hold, while more bullish voices such as Berenberg Bank ($62) and Argus Research ($60, Buy) sit near the top. The average is therefore best understood as a midpoint of opinion, not a forecast of a specific outcome, and it should not be read as a published consensus guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Rating momentum has been choppy. Sanofi received downgrades from Morgan Stanley (to Equal Weight), BNP Paribas (to Neutral), Barclays (to Equal Weight), and Guggenheim (to Neutral) between late 2025 and mid-2026. After the third-quarter report, however, several European brokers raised their euro-denominated targets, and BNP Paribas upgraded the stock back to Outperform — a sign that near-term earnings momentum is reviving confidence.

Current Market Position and Path Toward the Target

The ADR last closed near $46.52, leaving a required move of about 18% to reach $55. That is a substantial advance for a low-beta, dividend-paying healthcare name, though it is well within the historical range the shares have traded.

Fundamentally, the path is anchored by Dupixent, the inflammation drug co-marketed with REGN, which continues to beat expectations. Sanofi reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, with business EPS up about 19.6%, and it raised full-year guidance. The shares pay a dividend near $2.42 annually — a yield above 5% at current prices — which provides downside support but also signals a more defensive investor base.

Factors That Could Support a Move Toward the Target

  • Continued Dupixent outperformance and uptake in new indications across immunology and respiratory disease.
  • Growth in vaccines and recently launched medicines, reducing reliance on any single product.
  • Analyst revisions: post-earnings target increases and at least one upgrade suggest EPS estimates are being revised upward, which typically supports a stock price target.
  • An undemanding valuation on forward earnings, plus a dividend yield above 5%, which can attract income-oriented buyers.

Factors That Could Prevent the Target From Being Reached

  • Patent expiration (loss of exclusivity, or LOE) risk beyond Dupixent's peak years, a recurring concern for large pharma franchises.
  • Currency headwinds: as a euro-based company, a stronger dollar mechanically reduces the ADR's reported results and can pressure the shares.
  • Valuation compression if pipeline setbacks or competitive pressure from rivals in immunology and vaccines emerge.
  • Residual analyst skepticism, with several brokers still at Hold and targets clustered below $57, indicating no broad conviction for a breakout.

Technical Levels and Market Structure

The shares have traded in a 52-week range of roughly $39 to $51. A meaningful resistance level sits near the prior high in the $50–$51 zone, which the stock must clear before the $55 target becomes realistic. On the downside, support has formed near the mid-$40s, with a firmer floor near the $39–$40 area reached in October. The psychological $50 level is likely to act as both a technical and sentiment barrier on the way higher.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of about 12 months, though individual analysts use differing periods and assumptions. Investors weighing the $55 target should watch quarterly results and guidance, Dupixent prescription trends, any regulatory decisions across the pipeline, foreign-exchange movements, and further analyst target revisions. The next earnings date, dividend announcements, and key clinical readouts are the most direct catalysts for re-rating the shares. From what I see, tracking these elements closely helps clarify whether the average target holds as a realistic benchmark.

AI Daily Buy/Sell Signals

I’ve found Tickeron’s AI Daily Buy/Sell Signals helpful for monitoring names like SNY in real time. The tool uses artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on shifting market conditions and technical behavior. It gives a data-driven way to stay on top of momentum changes without reviewing every chart manually, which fits well into a routine review of healthcare holdings and broader sector trends.

Final Assessment

Reaching $55 would require Sanofi to climb roughly 18% from its latest close, a substantial but plausible move if Dupixent keeps compounding and analyst estimates keep rising. The central target is a statistical midpoint of a wide analyst range — roughly $45 to $63 — rather than a single confident forecast, and the recent mix of downgrades followed by target increases shows how divided the Street remains. Strong product momentum and an attractive dividend argue for support, while LOE risk, currency swings, and a heavy $50–$51 resistance zone argue for caution. The outcome will most likely hinge on execution in the immunology franchise and the pace of estimate revisions over the coming quarters. I’m watching this closely as the next few quarters unfold.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SNY

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


SNY in upward trend: price rose above 50-day moving average on October 29, 2026

SNY moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend. In 29 of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 57%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The 10-day moving average for SNY crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 53%.

Following a +0.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in 154 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.

The Aroon Indicator entered an Uptrend today. In 160 of 284 cases where SNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.

Bearish Trend Analysis

The 10-day RSI Indicator for SNY moved out of overbought territory on November 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 10 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 45%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 68 cases where SNY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 51%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SNY as a result. In 52 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.

The Moving Average Convergence Divergence Histogram (MACD) for SNY turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 19 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 40%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.

SNY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. SNY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 71 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 61, placing this stock worse than average.

The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.629) is normal, around the industry mean (-1.421). P/E Ratio (28.596) is within average values for comparable stocks, (21.700). SNY's Projected Growth (PEG Ratio) (27.976) is very high in comparison to the industry average of (5.738). SNY's Dividend Yield (0.169) is considerably higher than the industry average of (0.038). P/S Ratio (1.829) is also within normal values, averaging (4.033).

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -13%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -6%. OGN experienced the highest price growth at -0%, while SCLX experienced the biggest fall at -63%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 59%. For the same stocks of the Industry, the average monthly volume growth was 59% and the average quarterly volume growth was 35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 36
Price Growth Rating: 50
SMR Rating: 61
Profit Risk Rating: 61
Seasonality Score: 13 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a producer of pharmaceutical products

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
46, Avenue de la Great Army
Phone
+33 153774000
Employees
74846
Web
https://www.sanofi.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.